Cefepime Hydrochloride Injection shortage
Cefepime Hydrochloride Injection is currently listed in shortage by the FDA. The FDA lists 2 affected products. This page was last refreshed from FDA data on Sep 17, 2026.
Fresenius Kabi is permanently stopping production of cefepime hydrochloride injection. The same medicine in both the 1 g and 2 g strengths is still listed as available from other manufacturers, including Hikma, Hospira, Sagent, and WG Critical Care.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Cefepime Hydrochloride Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Feb 10, 2026Currently in shortage2 of 2 products affected.
-
Feb 10, 2026First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Cefepime Hydrochloride, Injection, 2 g (NDC 63323-340-20) | — | — | Discontinuation of the manufacture of the drug. | — |
| To Be Discontinued | Cefepime Hydrochloride, Injection, 1 g (NDC 63323-326-20) | — | — | Discontinuation of the manufacture of the drug. | — |
These rows are manufacturer reports to the FDA for Cefepime Hydrochloride Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Cefepime Hydrochloride Injection? options further down this page.
Why is Cefepime Hydrochloride Injection in shortage?
Fresenius Kabi USA has reported to the FDA that they are permanently stopping the manufacturing of two specific versions of cefepime hydrochloride injection — the 1 g and 2 g vials. They didn't share a specific public reason for this decision beyond stating it is a discontinuation of manufacture for both of these products.
It's worth knowing that this report only reflects what Fresenius Kabi has filed with the FDA. It doesn't mean cefepime injection as a whole is going away — other manufacturers may still be producing their own versions of this antibiotic and are listed separately.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Cefepime Hydrochloride Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Cefepime Hydrochloride Injection?
Cefepime Hydrochloride Injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.
This shortage record covers both strengths — the 1 g and 2 g — and neither has an available source from the reporting manufacturer right now. The reason listed for both is that this manufacturer, Fresenius Kabi USA, is discontinuing its production of the drug. Because this is a discontinuation rather than a temporary delay, this particular supply may not be coming back from that maker. Please know, though, that this report reflects only the manufacturer who filed it — other companies still make the same medicine.
Here is what I suggest, in order:
- Do not stop, skip, or change your treatment on your own. This is a prescriber-managed injection, and your care team should guide any change.
- Ask your pharmacy or care team about sourcing the same medicine from another maker. Cefepime is also listed from Hikma, Hospira, Sagent, WG Critical Care, and Apotex — though it may not be in local stock.
- If your exact product cannot be found, ask your prescriber or pharmacist about the best option for you.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls. This is general national information and may not match your local pharmacy's stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Cefepime Hydrochloride Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Cefepime Hydrochloride Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Cefepime Hydrochloride | CEFEPIME HYDROCHLORIDE 1 g/1 | Injection, Powder, For Solution · Intramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | 00143-9382-10 |
| Cefepime Hydrochloride | CEFEPIME HYDROCHLORIDE 2 g/1 | Injection, Powder, For Solution · Intravenous | Hikma Pharmaceuticals USA Inc. | 00143-9383-10 |
| Cefepime | CEFEPIME HYDROCHLORIDE 1 g/1 | Injection, Powder, For Solution · Intramuscular, Intravenous | Hospira, Inc. | 00409-9566-10 |
| Cefepime | CEFEPIME HYDROCHLORIDE 2 g/1 | Injection, Powder, For Solution · Intravenous | Hospira, Inc. | 00409-9735-10 |
| Cefepime | CEFEPIME HYDROCHLORIDE 1 g/20mL | Injection, Powder, For Solution · Intramuscular, Intravenous | Sagent Pharmaceuticals | 25021-0121-20 |
| Cefepime | CEFEPIME HYDROCHLORIDE 2 g/20mL | Injection, Powder, For Solution · Intravenous | Sagent Pharmaceuticals | 25021-0122-50 |
| Cefepime | CEFEPIME HYDROCHLORIDE 1 g/1 | Injection, Powder, For Solution · Intramuscular, Intravenous | WG Critical Care, LLC | 44567-0130-10 |
| Cefepime | CEFEPIME HYDROCHLORIDE 2 g/1 | Injection, Powder, For Solution · Intravenous | WG Critical Care, LLC | 44567-0131-10 |
| Cefepime | CEFEPIME HYDROCHLORIDE 1 g/1 | Injection, Powder, For Solution · Intramuscular, Intravenous | Apotex Corp. | 60505-6144-04 |
| Cefepime | CEFEPIME HYDROCHLORIDE 2 g/1 | Injection, Powder, For Solution · Intravenous | Apotex Corp. | 60505-6145-04 |
| Cefepime | CEFEPIME HYDROCHLORIDE 100 g/1 | Injection, Powder, For Solution · Intravenous | SAMSON MEDICAL TECHNOLOGIES LLC | 66288-8100-01 |
Therapeutic equivalents & pricing 25 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Cefepime 1 g | Hospira, | 10 vials | $3.731 | AP | Availability likely |
| Cefepime 1 g | WG | 10 vials | $3.731 | AP | Availability likely |
| Cefepime 1 g | WG | 10 vials | $3.731 | AP | Availability likely |
| Cefepime 1 g | Apotex | 10 vials | $3.731 | AP | Availability likely |
| Cefepime 1 g | Apotex | 10 vials | $3.731 | AP | Availability likely |
| Cefepime 1 g | Fresenius | 10 vials | $3.731 | AP | Availability likely |
| Cefepime Hydrochloride 2 g | Hikma | 10 vials | — | AP | FDA listed |
| Cefepime Hydrochloride 2 g | Hikma | 10 vials | — | AP | FDA listed |
| Cefepime Hydrochloride And Dextrose 2 g/50mL | B. | 50 ml | — | — | FDA listed |
| Cefepime 1 g/50mL | Baxter | 50 ml | — | — | FDA listed |
| Cefepime 2 g | Hospira, | 10 vials | — | AP | FDA listed |
| cefepime 2 g/20mL | Sagent | 10 vials | — | AP | Discontinued |
| Cefepime 2 g | WG | 10 vials | — | AP | FDA listed |
| Cefepime 2 g | WG | 10 vials | — | AP | FDA listed |
| Cefepime 2 g | Apotex | 10 vials | — | AP | FDA listed |
| Cefepime 2 g | Apotex | 1 vial | — | AP | FDA listed |
| Cefepime 2 g | Apotex | 10 vials | — | AP | FDA listed |
| Cefepime 2 g | Fresenius | 10 vials | — | AP | FDA listed |
| Cefepime 2 g | Qilu | 10 vials | — | AP | FDA listed |
| Cefepime Hydrochloride 1 g | Hikma | 10 vials | — | AP | FDA listed |
| Cefepime Hydrochloride 1 g | Hikma | 10 vials | — | AP | FDA listed |
| Cefepime Hydrochloride And Dextrose 1 g/50mL | B. | 50 ml | — | — | FDA listed |
| cefepime 1 g/20mL | Sagent | 10 vials | — | AP | Discontinued |
| Cefepime 1 g | Apotex | 1 vial | — | AP | FDA listed |
| Cefepime 1 g | Qilu | 10 vials | — | AP | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Cefepime Hydrochloride Injection — that fall in the same broad treatment class (cephalosporin antibiotics - 4th generation) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other anti-infective shortages
Cefepime Hydrochloride Injection shortage FAQs
Is Cefepime Hydrochloride Injection in shortage?
Which products are affected?
When will Cefepime Hydrochloride Injection be available again?
Can I still get Cefepime Hydrochloride somewhere?
What should I do if I take Cefepime Hydrochloride Injection?
Still have a question about the Cefepime Hydrochloride Injection shortage?
Ask a pharmacist about this shortage →View Cefepime Hydrochloride Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.